Towards improved therapy selection and targeted treatment for nasopharyngeal carcinoma. A proof-of-concept pilot study for somatostatin receptor 2 imaging with [68Ga]Ga-DOTA-TOC PET/CT: the NACASOR trial

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520689-23-00

Acronym

21477

Enrollment

Registered

2025-07-14

Start date

2025-09-22

Completion date

Unknown

Last updated

2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Brief summary

[68Ga]Ga-DOTA-TOC PET imaging is considered feasible in patients with EBV related NPC if we can visualize and quantify tumor [68Ga]Ga-DOTA-TOC uptake in at least seven out of ten patients and complete repeat imaging in at least six patients.

Detailed description

SUVpeak values of primary tumors and lymph node metastases on the pre-treatment scan., SUVmean values in normal tissues and organs. Healthy lymph nodes will be defined as SUVpeak., Tumor SSTR2 expression determined by IHC.

Interventions

DRUG68Ga-Dotatoc

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
[68Ga]Ga-DOTA-TOC PET imaging is considered feasible in patients with EBV related NPC if we can visualize and quantify tumor [68Ga]Ga-DOTA-TOC uptake in at least seven out of ten patients and complete repeat imaging in at least six patients.	—

Secondary

Measure	Time frame
SUVpeak values of primary tumors and lymph node metastases on the pre-treatment scan., SUVmean values in normal tissues and organs. Healthy lymph nodes will be defined as SUVpeak., Tumor SSTR2 expression determined by IHC.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026